A strong patent position has been generated for both targets, IFN-alpha- and FGF-2-encoding mRNAs. The IFN-alpha patent is most advanced. Notice of allowance has been granted. For FGF-2 the favorable international preliminary report on patentability (IPRP) has been approved by the European patent office.
Recently, the divisional patent application for our IFN-alpha encoding mRNAs as a therapeutic treatment of Covid-19-infected patients has been filed.